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Ovarian cancer spreads intraperitoneally and forms fluid, whereby the diagnosis and therapy often become delayed. As the
complement (C) system may provide a cytotoxic effector arm for both immunological surveillance and mAb-therapy, we have
characterised the C system in the intraperitoneal ascitic fluid (AF) from ovarian cancer patients. Most of the AF samples showed
alternative and classical pathway haemolytic activity. The levels of C3 and C4 were similar to or in the lower normal range when
compared to values in normal sera, respectively. However, elevated levels of C3a and soluble C5b-9 suggested C activation in vivo.
Malignant cells isolated from the AF samples had surface deposits of C1q and C3 activation products, but not of C5b-9 (the
membrane attack complex; MAC). Activation could have become initiated by anti-tumour cell antibodies that were detected in the
AFs and/or by changes on tumour cell surfaces. The lack of MAC was probably due to the expression of C membrane regulators
CD46, CD55 and CD59 on the tumour cells. Soluble forms of C1 inhibitor, CD59 and CD46, and the alternative pathway inhibitors
factor H and FHL-1 were present in the AF at concentrations higher than in serum samples. Despite the presence of soluble C
inhibitors it was possible to use AF as a C source in antibody-initiated killing of ovarian carcinoma cells. These results demonstrate
that although the ovarian ascitic C system fails as an effective immunological surveillance mechanism, it could be utilised as an effector
mechanism in therapy with intraperitoneally administrated mAbs, especially if the intrinsic C regulators are neutralised.
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Ovarian cancer is the sixth most common malignant neoplasm in
women worldwide (Pisani et al, 2002). Despite maximal cyto-
reductive surgery and chemotherapeutic regimens, the overall
survival rate is still below 40% (Bjrge T et al, 1998). This is mainly
due to innate or acquired drug resistance and the fact that the
majority of tumours have progressed to an advanced stage at the
time of diagnosis (Bjrge T et al, 1998; Baekelandt et al, 2000).
Ovarian carcinomas are the most common primary tumours
that lead to the production of free abdominal fluid or ascites (AF)
(Zeimet et al, 1998). However, the mechanisms of generation and
the role of ascites in the biology of ovarian cancer are widely
unknown. Usually, at the time of diagnosis, the cancer has already
spread beyond the ovaries, and symptoms related to the presence
of free abdominal fluid are often the first manifestation of the
disease (Zeimet et al, 1998). Characteristically, the malignant cells
often remain confined to the abdominal cavity in direct contact
with AF both as peritoneal implants and as free-floating tumour
cells, thereby complicating the complete surgical removal of the
tumour cells (Zeimet et al, 1998).
The complement (C) system is a major component of innate
immunity. It eliminates invading microorganisms, transformed
cells and molecular aggregates from tissues and biological fluids
(Walport, 2001). Complement activation occurs through three
convergent pathways, in which the C components are usually
activated by sequential proteolytic cleavages and/or by binding to
previously activated components. This results in the release of
chemotactic factors and cell-activating anaphylatoxins, deposition
of opsonic fragments and formation of the membrane attack
complex (MAC) (Walport, 2001). Although C may become
activated on tumour cells by tumour-binding antibodies (Magyar-
laki et al, 1996), immune complexes (Lucas et al, 1996) or as a
consequence of apoptosis (Matsumoto et al, 1997) or proteolytic
processes (Niculescu et al, 1992; Yamakawa et al, 1994; Bjrge L
et al, 1997a), the cytotoxic activity of C is insufficient as an
effective immunological surveillance mechanism against tumours
(Gorter and Meri, 1999; Jurianz et al, 1999). Immunotherapy with
C-activating mAbs in the treatment of solid tumours has so far
shown only limited success (Dillman, 1994; Gruber et al, 1996).
The ‘humanised’ anti-CD20 mAb, rituximab has shown an overall
response rate of over 50% (Maloney et al, 1997) in the treatment of
non-Hodgkin’s lymphomas. This mAb acts by activating C and by
causing antibody-dependent cellular cytotoxicity and apoptosis
(Golay et al, 2000; Harjunpaa et al, 2000). The limited suscept-
ibility of solid tumour cells to C, can, in part, be explained by the
presence of intrinsic cellular C resistance mechanisms and by
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slimited accessibility of mAbs and C components to the tumours
(Bjrge L et al, 1997a; Hakulinen and Meri, 1998; Gorter and Meri,
1999; Jurianz et al, 1999).
Complement resistance of both malignant tumour cells and
normal cells is mediated by membrane-bound C regulatory
proteins that either limit the formation of the C3/C5 convertase
enzymes, or the assembly of the MAC (Morgan and Meri, 1994;
Gorter and Meri, 1999; Jurianz et al, 1999; Walport, 2001). The key
C enzymes, C3/C5 convertases, are inhibited by the following C
regulatory proteins; complement receptor type 1 (CR1, CD35),
decay-accelerating factor (DAF, CD55) and membrane cofactor
protein (MCP, CD46). These molecules prevent the assembly and
promote the decay of the C3/C5 convertase complexes (CR1 and
DAF), or serve as cofactors for the plasma serine protease factor I,
which irreversibly inactivates C4b and C3b (CR1 and MCP).
Protectin (CD59), on the other hand, inhibits the formation and
function of MAC complexes on cell surfaces. In addition, nucleated
cells have the capacity to remove MAC-containing membrane
particles from their cell surfaces by vesiculation or internalisation
(Morgan, 1992). Some tumour cells have also been found to secrete
the soluble C regulators factor H (FH) and factor H-like protein 1
(FHL-1) (Junnikkala et al, 2000, 2002).
Antibody responses develop in ovarian cancer, and tumour-
reactive immunoglobulins directed both against intracellular
proteins and surface antigens have been demonstrated in patient
sera (Chinni et al, 1997; Taylor and Gercel-Taylor, 1998;
Abendstein et al, 2000; Gercel-Taylor et al, 2001). The antibody
levels increase as the disease progresses (Taylor and Gercel-Taylor,
1998). Furthermore, ascitic immunoglobulins of IgM and IgG
classes have been described (Silburn et al, 1984a,b; Rao and
Hanjani, 1988). They are present either as circulating free
antibodies, in immune complexes, or bound to tumour cells and
cellular fragments (Silburn et al, 1983; Runowicz et al, 1989;
Kawata and Sekiya, 1998; Taylor and Gercel-Taylor, 1998). Despite
the fact that they are partially tumour-reactive, they fail to destroy
the tumour cells (Taylor and Gercel-Taylor, 1998).
Factors of the C system (Runyon et al, 1985; Mal et al,
1991; Alexandrakis et al, 2001), chemoattractants and opsonic
activity (Runyon et al, 1985; Mal et al, 1991) have been
described in AF from ovarian cancer patients. The ascitic C
system, although incompletely characterised, has been given
the role as a protector against spontaneous bacterial peritonitis
(Runyon et al, 1985).
In our previous studies, we have described the expression of the
C regulators MCP, DAF and CD59 on ovarian carcinoma cells both
in solid tumours and in culture (Bjrge L et al, 1997a). DAF and
CD59 appeared to be the main factors that protected malignant
ovarian cells against C-mediated killing. Furthermore, FH and
FHL-1 were found to be produced by ovarian tumour cells, and in
solid ovarian tumours FH and FHL-1 were present in the apical
tumour cell layers (Junnikkala et al, 2002).
It has been suggested that the AF represents an appropriate
environment for studies of tumour biology and locally occurring
host–tumour interactions (Zeimet et al, 1998). In the present
study, we have investigated the AF C system in ovarian cancer
patients to more precisely understand the local humoral anti-
tumour immune responses, and to reveal mechanisms whereby the
growing tumours escape the host’s innate immune system. As
intraperitoneal delivery of mAbs could potentially be used in the
treatment of ovarian cancer (Rubin, 1993), the susceptibility of
malignant ovarian cells to C-mediated killing with AF as a C source
was also examined.
MATERIALS AND METHODS
Collection and storage of AF samples and preparation of
ascitic tumour cells
The study was approved by the Regional Ethical Committee of
Western Norway (Jnr. 234/97-81.97), and informed consents were
obtained from the patients. Ascitic fluid samples were obtained in
a prospective, nonselective fashion from patients referred to the
Haukeland University Hospital (Bergen, Norway) for the treatment
of presumed ovarian cancer. The histopathological diagnoses were
obtained according to the 1986 revised staging system of the
Fe ´de ´ration International d’Obste ´trique (FIGO, 1987), at the
Department of Pathology, The Gade Institute, Haukeland Uni-
versity Hospital. Ascitic fluid samples were obtained during
laparotomy immediately after the peritoneal cavity was opened
and taken into silicone-coated tubes or tubes containing 1mM
EDTA (final concentration). The samples were cooled to 41C and
transported to the laboratory. The samples from the patients
(n¼16) (Table 1) were centrifuged at 1100g at 41C for 10min to
separate cells and other debris from the fluid phase. The cell-free
fluid was aliquoted and stored at  701C until used. Samples from
Table 1 Clinical characteristics of the patient group
Patient no. Age Diagnosis Stage Histology
1 71 Ovarian cancer IIIb Serous cystadenocarcinoma
2 60 Ovarian cancer IIIc Serous cystadenocarcinoma
3 75 Ovarian cancer III Serous cystadenocarcinoma
4 30 Ovarian cancer IIIc Endometroid adenocarcinoma
5 44 Ovarian cancer IV Papillary serous cystadenocarcinoma
6 52 Ovarian cancer Ib Endometroid adenocarcinom
7 67 Ovarian cancer IIIc Papillary serous cystadenocarcinoma
8 59 Ovarian cancer IIIc Papillary serous cystadenocarcinoma
9 72 Ovarian cancer IV Papillary serous cystadenocarcinoma
10 72 Ovarian cancer IV Papillary serous cystadenocarcinoma
11 74 Ovarian cancer IIIc Papillary serous cystadenocarcinoma
12 57 Ovarian cancer IIIc Mucinous adenocarcinoma
13 65 Endometrial cancer Ic Endometroid adenocarcinoma
14 56 Fallopian tube cancer IIIc Adenocarcinoma from the left tube
15 50 Breast cancer Serous cystadenocarcinoma
16 59 Cystadenoma in the left ovary Serous cystadenoma
17 68 Alcoholic liver cirrhosis
18 64 Chronic active hepatitis (seronegative), liver cirrhosis and hepatorenal syndrome
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stwo patients with nonmalignant AF were obtained by paracentesis
at the Medical Department, Division of Gastroenterology, Hauke-
land University Hospital, and processed in the same way as the AF
from the patients with ovarian tumours.
Tumour cells were isolated from AF samples from two patients
(patients no. 2 and 10) by a density gradient separation method.
Conically shaped glass tubes (15ml; Schott Glasswerke, Mainz,
Germany) or plastic vials (50ml; Elkay, Shrewsbury, USA) were
used for the preparation of density gradients. The density
separation liquid (Lymfoprep solution
s; Nycomed, Oslo, Norway)
was loaded in three equally sized layers. The bottom layer
consisted of Lymfoprep solution
s (1.077gml
 1), the middle layer
(1.059gml
 1) of a mixture of 2.25vol. Lymfoprep
s and 0.75vol.
Krebs Hepes Ringer (KHR) solution (136.9mM NaCl, 5.36mM KCl,
0.34mM Na2HPO4 2H2O, 0.35mM KH2PO4, 0.8mM MgSO4 7H2O,
1m M Hepes, pH 7.4) without Ca
2þ, and the top layer
(1.030gml
 1) of a mixture of 1vol. Lymfoprep
s and 2vol. of
the KHR solution. All density gradient fractions were supplemen-
ted with 1mM EDTA. The AF samples used for cell isolation were
all supplemented with 1mM EDTA and kept at room temperature
all the time. The AF was carefully loaded onto the density gradients
and centrifuged at 1500gav for 20min. After centrifugation, several
cell bands appeared. The main tumour cell fraction (T-fraction)
was found at the interface between the upper and middle density
fractions as a clear band in samples having many tumour cells. At
the interface between the middle and lower gradients, most of the
inflammatory cells (B-fraction) were found, along with a varying
degree of tumour cells. Routinely, the T- and B-fractions were
collected as they contained more than 80% of all tumour cells.
Small aliquots of cells from the T- and B-fractions were routinely
spun on a cytocentrifuge (1250r.p.m., 10min), and the cells were
mounted on silicone-coated microscope slides (Dako, Glostrup,
Denmark). The samples were fixed in acetone (Merck, Darmstadt,
Germany) for 20min and air-dried. The cells were identified as
tumour cells by cytology (staining with Diff Quick and Giemsa),
and by immunocytochemistry staining for the tumour antigens
CA125 and Ber-EP4.
Antibodies and sera
A rat hybridoma cell line (YTH53.1) producing a mAb to human
CD59 was originally obtained from Professor H Waldmann (Sir
William Dunn School of Pathology, Oxford, UK). YTH53.1 (IgG2b)
was purified from cell culture supernatant using a Protein G
Sepharose 4 Fast Flow affinity column (Pharmacia BioTech,
Uppsala, Sweden). Mouse mAbs to DAF (CD55; BRIC230 and
BRIC216; IgG1) and CD59 (BRIC229; IgG2b) were purchased from
the International Blood Group Reference Laboratory (IBGRL,
Bristol, UK). Murine mAb to human MCP (CD46; J4-48; IgG1) was
purchased from Immunotech (Marseille, France) or obtained as a
gift (GB24; IgG1) from Drs K Liszewski and JP Atkinson
(Washington University School of Medicine, St Louis, MO, USA).
Murine mAb to human TCC (aE11; IgG2a) and rabbit polyclonal
antibodies to human C1q, C3c, IgG and IgM were all obtained from
Dako. Peroxidase-conjugated rabbit immunoglobulins (Igs) to
mouse IgG, peroxidase-conjugated-swine Igs to rabbit IgG,
peroxidase-conjugated rabbit Igs to human IgG and peroxidase-
conjugated rabbit Igs to human IgM were purchased from Jackson
ImmunoResearch Laboratories (Burlingame, CA, USA). Normal
human serum (NHS) that served as a source of C was prepared
from coagulated blood of healthy laboratory personnel and stored
in aliquots at  701C until used.
Cell lines
The human ovarian adenocarcinoma cell lines (Caov-3, SK-OV-3
and SW626), human ovarian teratocarcinoma cell line (PA-1) and
human endothelial cell line (HUV-EC-C) were all obtained from
American Type Culture Collection (ATCC, Manassas, VA, USA).
The cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco, Paisley, UK) supplemented with 10% heat-
inactivated foetal calf serum (FCS; Gibco), 2mML -glutamine (Bio
Whittaker, Walkersville, MD, USA) and antibiotics (10Uml
 1 of
penicillin (AL, Oslo, Norway) and 10mgml
 1 of streptomycin
(Glaxo, Greenford, UK)) at 371C in a humidified atmosphere with
5% CO2. Cells were grown in 75cm
2 cell culture flasks (Costar,
Cambridge, MA, USA) and subcultured twice a week. Suspensions
of the cells were obtained by incubating the cell cultures with
Versene/EDTA (Gibco). Thereafter, the cells were washed twice in
growth medium and resuspended.
Secreted or shed molecules from the different cell lines were
collected in the following way: the cell lines were grown in 75cm
2
cell culture flasks until 90% confluent, washed three times with a
cell culture medium containing no FCS, and fresh medium without
supplements was added. After a 48-h incubation period, the cell
cultures were harvested and centrifuged twice at 500 and 800g for
10min, before the supernatants were filtered through ultrafilters
with a pore size of 0.45mm (Minisart
s, Sartorius AG, Go ¨ttingen,
Germany). The samples were further concentrated (100 )i n
Biomax concentrators (Millipore, Bedford, MA, USA) with a cutoff
limit of 10kDa.
Concentrations of IgM, IgG, C3, C4, C1-inhibitor and factor
Hi nA F
The concentrations of IgM, IgG, C3 and C4 were determined using
precipitating antisera in a Nephelometer Analyzer (Behringwerke
AG, Marburg, Germany). The C1-inhibitor (C1INH) concentration
was determined by radial immunodiffusion (Nor-Partigen; Beh-
ringwerke AG). Factor H and FHL-1 concentrations in the AF
samples were determined by an enzyme-linked immunoabsorbent
assay (ELISA) as described previously (Junnikkala et al, 2002).
Samples of AF were assayed for total protein content using the Bio-
Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA)
according to the instructions from the manufacturer.
CD59, DAF and MCP in AF samples and in cell culture
supernatants
Ascitic fluid samples and concentrated cell culture supernatants
were electrophoresed in 10% SDS–PAGE slab gels under
nonreducing conditions. The proteins were transferred onto
nitrocellulose filters. After blocking the membranes with 5%
nonfat milk powder in phosphate-buffered saline (PBS), pH 7.4 for
30min, the filters were incubated overnight at þ41C with mAbs
directed against CD46 (J4-48; 0.5mgml
 1), CD55 (BRIC230 or
BRIC216; 0.5mgml
 1) or CD59 (BRIC229; 0.5mgml
 1) diluted in
PBS containing 5% nonfat milk power. In controls, the primary
antibodies were omitted or replaced with an irrelevant antibody of
the same subclass as the specific mAb. After washing with PBS, the
bound antibodies were visualized using peroxidase-conjugated
anti-mouse IgG and a chemiluminescence substrate (SuperSignal
s
ULTRA Substrate; Pierce Chemical Company, Rockford, IL, USA)
according to the instructions from the manufacturer.
Analysis of relative amounts of soluble and membrane
forms of CD59 in AF
Triton X-114 (TX-114) phase separation was used to separate the
soluble and phospholipid-anchored forms of CD59 in AF (Lehto
and Meri, 1993). TX-114 (Sigma Chemical Co, St Louis, MO, USA)
was added at a concentration of 0.5% to cell-free AF at þ41C from
10 patients (seven patients with ovarian cancer and three patients
with other gynaecological diseases). The samples were incubated at
371C for 3min until clouding occurred. The detergent and aqueous
phases were separated by centrifugation at 3000g for 3min at
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sþ221C. Samples of the different phases were analysed by SDS–
PAGE and immunoblotting for the presence of CD59 as described
above. The aqueous phase contained exclusive CD59 that was fee
of attached phospholipids.
Complement activation in vivo and haemolytic C activity in
AF
In vivo C activation in AF samples containing 1mM EDTA was
determined by analysing levels of C3a and TCC (SC5b-9). C3a
levels were measured using an ELISA- kit from Quidel according to
the instructions from the manufacturer. SC5b-9 concentrations
were determined by an ELISA assay as described previously (Lehto
and Meri, 1993).
The haemolytic activities of the alternative and classical C
pathways in AF samples (without additives) were determined by
radial diffusion in gels containing antibody-coated chicken or
guinea pig erythrocytes, respectively (The Binding Site Ltd.,
Birmingham, England). Serial dilutions of an NHS pool with
known C activity were used to generate standard curves.
Ascitic fluid C-mediated lysis of ovarian tumour cells
Single cell suspensions of the PA-1 and Caov-3 cell lines were
labelled with sodium-chromate (
51Cr) by incubating 6 10
6 cells
with 40mCu of
51Cr (Amersham, Cardiff, UK) in 1ml of DMEM for
2hat þ371C. After incubation, the cells were washed three times
in DMEM. To remove unbound
51Cr, the cells were further
incubated in 1ml of DMEM for 30min at þ371C. After two washes
in DMEM, the cell number was adjusted to 2 10
6cellsml
 1.
Duplicate aliquots (50ml) of the
51Cr-labelled cells were incubated
for 15min at room temperature with appropriate dilutions of the
YTH53.1 mAb in 100ml. Aliquots of AF (from different patients) or
NHS at different dilutions were added, and the cells were further
incubated for 60min at þ371C. The radioactivity released into the
medium was counted from 100ml portions of the supernatants.
Final concentrations of the reagents are provided in the respective
figure legends. In controls, DMEM was used instead of the
reactants. The maximum
51Cr release was obtained from cells
exposed to 1.0% Nonidet-P40 (NP-40). Spontaneous
51Cr release
was counted from the supernatants of the cells incubated with the
cell culture medium only. The cell lysis was calculated as a
percentage of the maximum released radioactivity: ((released
radioactivity spontaneous release)/(maximum released radioacti-
vity spontaneous release)) 100%.
Immunohistochemistry analysis
Cytospin slides made from AF samples from patients no. 2 and 10
were initially immersed in PBS containing 1% BSA for 5min to
rehydrate the sections. They were further incubated with 0.3%
H2O2 diluted in PBS for 15min. The cytospin slides were then
incubated with 10% heat-inactivated NHS diluted in PBS for
30min at room temperature, before being incubated with poly-
and monoclonal antibodies against C1q, C3c, TCC, DAF, MCP and
CD59 diluted in PBS overnight at 41C. Peroxidase-labelled rabbit
anti-mouse IgG or swine anti-rabbit Ig diluted in PBS were
subsequently applied for 60min. The cytospin slides were finally
treated with a diaminobenzidine (Sigma)-substrate-containing
buffer. Control preparations were incubated with corresponding
amounts of irrelevant mouse monoclonal antibodies or normal
rabbit serum. All cytospin slides were counterstained with
haematoxylin, mounted in Mowiol, and analysed using a Nikon
light microscope (Melville, NY, USA).
IgG responses in AF against ovarian cancer cell antigens
Ovarian cancer cell (Caov-3, PA-1, SK-OV-3 and SW626)
membranes were isolated and solubilised. The membrane proteins
were separated by SDS–PAGE, and immunoblotting was employed
to examine if the AF samples contained IgG with specificity
directed against ovarian cancer cell antigens. HUV-EC-C cells were
used for comparison. Suspensions of the cells were obtained by
incubating the cell cultures with 0.02% EDTA. After washing twice,
the cells were incubated in 1ml of ice-cold hypotonic lysis buffer
(10mM Tris and 10mM NaCl, pH 7.4) containing protease
inhibitors (Cmpletet Mini, Roche, Mannheim, Germany) for
10min. The plasma membranes in suspension were disrupted with
Table 2 Levels of immunoglobulins, total protein, complement factors and regulators in ascites fluids
Diagnosis No. IgG (gl
 1)IgM (gl
 1)Protein (gl
 1)C3(gl
 1)C4(gl
 1)C1INH (gl
 1)FH/FHL-1 (gl
 1) MCP DAF CD59
Ovarian cancer 1 7.698 0.329 84.0 0.466 o0.064 0.127 0.618 + (U)
a   +++
2 5.431 0.371 64.0 0.777 0.205 0.253 0.677 +   +
3 7.356 0.225 79.5 0.673 0.200 0.159 0.718 +   +++
4 5.106 0.211 74.5 0.786 0.136 0.240 1.498 + (L)   +
5 8.409 0.377 91.5 1.388 0.205 0.213 0.473    +
6 12.86 0.311 96.5 0.436 0.113 0.201 1.148   ++
7 7.293 0.315 86.5 0.929 0.190 0.241 0.543   ++
8 10.00 0.377 64.5 0.900 0.160 0.262 0.767    +
9 8.929 0.338 82.5 0.687 0.123 0.198 0.871 + (U)   ++
10 13.66 0.659 77.0 0.620 0.102 0.184 1.169 + (U)   +
11 7.825 0.445 91.5 0.898 0.125 0.173 0.375 + (U)   +
12 9.329 0.267 89.5 0.961 0.194 0.215 0.941   ++
Mean7s.d. 8.6672.58 0.3570.12 81.79710.40 0.7970.25 0.1570.05 0.2170.04 0.75870.312
Other gynaecological neoplasms 13 6.818 0.311 64.5 0.903 0.130 0.215 0.700   ++
14 38.75 0.516 107.5 0.889 0.104 0.175 0.821    ++++
15 o0.042 0.710 41.0 0.777 0.131 0.168 0.395    +
16 8.071 0.346 84.5 0.772 0.200 0.144 0.424    +++++
Liver failure 17 2.13 0.250 9.3 o0.177 o0.064 o0.031 0.016     
18 2.74 0.416 7.9 o0.177 o0.064 o0.031 0.050     
Serum NHS 8.0–18.0 0.6–2.7 62–76 0.5–1.5 0.15–0.50 0.12–0.24 0.335–0.587     
aU¼upper Mw form predominating; L¼lower Mw form predominating. For methods, see Materials and Methods. The values in normal human serum samples are shown for
comparison. They represent mean72 s.d. in 100 healthy blood donors.
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sa teflon pestle in a glass homogeniser and further incubated for
10min on ice. After removing the nuclei by centrifugation (twice at
1500g, 5min), the cell membranes were pelleted at 20000g for
15min. The membrane pellets were run in SDS–PAGE slab gels
(5–15%) under nonreducing conditions and transferred onto
nitrocellulose sheets. The strips of the nitrocellulose sheets were
incubated with AF samples diluted in PBS (1:800), and the bound
IgG was detected with peroxidase-conjugated anti-human IgG and
a chemiluminescence detection system.
RESULTS
Immunoglobulins, C components and regulators in AF
All the patients with neoplasms were previously untreated, and all
underwent surgery. The clinical characteristics of the patients are
summarised in Table 1.
To analyse factors needed in humoral immune responses, we
initially measured the concentrations of IgG, IgM and C
components in the AF samples (Table 2). The mean concentrations
of IgG (8.6672.58gl
 1) and IgM (0.3570.12gl
 1) in the ovarian
cancer patients’ AFs were lower than the average concentrations in
normal human sera, despite the fact that the total protein
concentrations in the malignant AFs were 93–140% of the serum
values. In comparison, the concentrations of IgG in a patient with
alcoholic liver cirrhosis (2.13gl
 1) and in a patient with chronic
active hepatitis (2.74gl
 1) were approximately 1/4 of the lower
limit measured for NHS (8.0–18.0gl
 1), while the IgM levels in
these samples were within the same range as in the malignant AF.
The levels of C3 (0.7970.25gl
 1) and C4 (0.1570.05gl
 1)i n
the AF samples were approximately the same or at the lower limit
measured for serum samples (0.5–1.5 and 0.15–0.50gl
 1,
respectively). The concentrations of C3 and C4 in the nonmalig-
nant AFs were below the threshold levels of the assays used for the
measurements. The C1INH-level (0.2170.04gl
 1) in malignant
AFs was similar to the one present in normal serum (range: 0.21–
0.24gl
 1). In contrast to most other parameters, the average
combined level of factor H and FHL-1 (0.75870.312gl
 1) in the
AF from ovarian cancer patients was higher than that in NHS
(0.46170.063gl
 1) (Junnikkala et al, 2002). In comparison, the
factor H/FHL-1 levels in the liver failure AF samples were very low
(0.016 and 0.050gl
 1).
Soluble forms of membrane bound C regulators in AF
Interestingly, in addition to C1INH and factor H/FHL-1, we
detected soluble forms of C membrane regulators in AF. By
immunoblotting, soluble MCP was detected in AF in seven out of
12 cases with ovarian cancer. The anti-MCP antibody reactive
bands (58 and 68kDa) comigrated with MCP from peripheral
blood cells. No MCP was detected in AF from patients suffering
from conditions other than ovarian cancer (Table 2).
Unlike MCP, no soluble form of DAF could be detected in any of
the samples tested (Table 2), while erythrocyte extracts run in the
same setups showed positive staining for DAF at 70kDa.
A characteristic anti-CD59 reactive smear around 20kDa was
detected in all AF samples tested. A semiquantitative comparison
of the amount of CD59 in the AF samples is shown in Table 2. To
determine whether CD59 was linked to membrane phospholipids,
AF samples from ovarian cancer patients were subjected to
partitioning with the TX-114 detergent. As shown in Figure 1,
CD59 was detected principally in the detergent phase that contains
the membrane-associated form of CD59 (Lehto and Meri, 1993).
The approximate relative amounts of CD59 in the aqueous and
detergent phases were found to be 20 and 80%, respectively, as
judged from the intensities of staining (n¼7). Similar results were
obtained when AF samples from the three patients with other
gynaecological diseases were examined.
25-
20-
14-
-CD59
M
w
 
(
k
D
a
)
Native sample Water phase TX-114
TX-114 extraction of AF
Figure 1 CD59 in ascites fluid (AF) has acyl-chains attached to it. The
Triton X-114 (TX-114) partitioning was used to separate soluble and
phospholipid-containing forms of CD59 in AF. TX-114 (0.5%) was added
to cell-free AF at þ41C. After an incubation at þ371C, the detergent and
water phases were separated by centrifugation. The native AF sample,
detergent and water phases of AF were run in nonreduced SDS–PAGE
(10%), transferred onto nitrocellulose membranes and probed with an anti-
CD59 mAb (BRIC229). CD59 was detected principally in the detergent
phase, indicating that the majority of CD59molecules still contained
membrane phospholipids.
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Figure 2 Immunoblotting analysis of C regulators in the concentrated
cell culture supernatants of Caov-3, PA-1, SK-OV-3 and SW626 ovarian
cancer cells. Confluent cultures of ovarian cancer cells were incubated with
serum-free cell culture medium for 48h. The centrifuged and filtered
(0.45mm) cell culture supernatants were concentrated (100 ). Aliquots
(20ml) were electrophoresed in 10% nonreducing SDS–PAGE slab gels
and blotted onto nitrocellulose membranes. The membranes were
incubated with antibodies to CD46 (J4-48), CD55 (BRIC 230 or 216),
CD59 (BRIC 229) and SP40,40.
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tumour cells
To analyse whether soluble forms of C membrane regulators could
originate from tumour cells, we examined concentrated cell culture
supernatants from Caov-3, SK-OV-3, PA-1 and SW626 cells by
immunoblotting (Figure 2). Our earlier FACS analysis showed
expression of MCP and CD59 on all the four cell lines and DAF
expression on the Caov-3, SK-OV-3 and SW626 cell lines, but not
on the PA-1 cell line (Bjrge L et al, 1997a). Supernatants from
Caov-3, PA-1 and SW626 cells showed two bands of 46 and/or
70kDa that reacted with the anti-CD46 mAb J4-48. No such
reactivity was seen in the concentrated SK-OV-3 medium. A
70kDa band was detected when the SW626 supernatant was
stained with the anti-CD55 mAbs BRIC216 and BRIC230. None of
the supernatants from the other cell lines showed detectable CD55.
The anti-CD59 mAb BRIC229 revealed bands of 21kDa in the
supernatants from all the cell lines. No bands could be detected in
the negative control, where the primary antibodies were omitted.
Haemolytic C activity and C activation products in the
patients’ AF samples
The median haemolytic activity of the classical C pathway in AF
(75Uml
 1) was within the range detected in NHS (50–100Uml
 1)
(Table 3). In only thee samples, no classical pathway activity was
detected (nos. 1, 14 and 16). Alternative pathway haemolytic
activity in AF samples (95%) was also similar to values in serum
(66–129%) (Table 3). No haemolytic activity of either pathway was
detected in the non-neoplastic AFs.
To analyse whether C activation had occurred in the AF samples,
the levels of C activation products C3a and SC5b-9 were measured.
The data are shown in Table 3. The levels of C3a were clearly
elevated (255271292ngml
 1) in the ovarian cancer patient AF
samples, as compared to values present in normal sera (26–
146ngml
 1) or in nonmalignant AF samples (240 and
1200ngml
 1). The same was also the case for levels of SC5b-9 in
AF samples. The ELISA measurements showed a mean SC5b-9
concentration of 6772ngml
 1 in the ovarian tumour AF samples.
However, the range was wide (0–20211ngml
 1; Table 3). No
SC5b-9 was detected in samples 7 and 11. In samples from patients
with liver failure (nos. 17 and 18), the values were 2493 and
1113ngml
 1, respectively. In conclusion, C activation to the
terminal stage had occurred in most, but not all AF samples from
ovarian tumour patients.
Sensitivity of ovarian tumour cells to ascites-mediated
cytotoxicity
The cytotoxic C activity in AF was examined by first sensitising
51Cr-labelled Caov-3 and PA-1 cells with a C-activating and CD59-
neutralizing mAb (YTH53.1) and exposing the cells to AF. Normal
human serum was used as a control source of C in the cell-killing
assay. Maximal killing of Caov-3 and PA-1 cells was obtained by
treating them with 1% NP-40 detergent. Both Caov-3 and PA-1
cells showed a weak dose-dependent lysis with NHS and AF in the
assay. Typical examples are shown in Figure 3. During a 60min
incubation at þ371C, using saturating concentrations of YTH53.1,
approximately 5 and 20% of the PA-1 cells were killed in the
presence of 33 and 66% of AF (sample no. 20), respectively
(Figure 3). In comparison, when PA-1 cells were subjected to C-
mediated killing with NHS as a source of C, 2 and 6% of them
became lysed in the presence of 33 and 66% of NHS, respectively.
However, when the Caov-3 cell line was examined in the same
assay, the tested serum sample showed stronger cytolytic activity
than the AF sample (no. 15) (Figure 3). No lysis of Caov-3 and
PA-1 cells was detected if YTH53.1 was omitted.
Immunostaining of the ovarian tumour cells for
membrane bound C regulators and C deposits
Isolated tumour cells from two patients were examined for C
regulators and possible deposits of C components. Decay-
accelerating factor was expressed on cells from both patients,
although only 57% (sample no. 2) and 78% (sample no 10) of the
tumour cells stained positive for DAF (Figure 4A). All the cells
from both patients expressed both MCP and CD59 (Figure 4B and
C). Although the intensity of staining was stronger for MCP than
for CD59, the staining patterns were similar; both membranous
and intracytoplasmic granular staining were seen. In comparison,
Table 3 Haemolytic C activities and C activation product levels in AF samples
Diagnosis Sample no. CH100CL (Uml
 1) CH100AP (% normal) C3a (ngml
 1) SC5b-9 (ngml
 1)
Ovarian cancer 1 o25 35 5100 2546
2 40 95 2750 11996
3 60 115 1800 20211
4 100 80 3600 18928
5 100 100 3600 12414
6 o25 95 1500 1511
7 o25 80 1100 o10
8 100 100 2000 2575
9 140 100 3000 4049
10 90 70 1375 2955
11 70 40 1000 o10
12 80 120 3800 4067
Mean7s.d. 68.13741.53 85.83726.61 255271292 677177208
Other gynaecological neoplasms 13 70 65 2750 o10
14 o25 50 6300 2946
15 90 60 7300 12659
16 o25 65 3500 12307
Liver failure 17 o25 — 240 2493
18 o25 — 1200 1133
Serum/range 50–100 66–129
Plasma/range 26–146 o100
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Deposits of C1q and C3d, but not of C5b-9, could be detected on
isolated tumour cells from both samples (Figure 5). The staining
pattern for C1q was a prominent circumferential, linear membrane
staining, while the C3d staining was weaker and less distinct. No
reactivity was seen when the primary antibody was replaced with
control antibodies.
Specific IgG responses in patients’ AF against ovarian
cancer cell antigens
In principle, C activation in AF against ovarian cancer cells could
have become initiated by antitumour antibodies in the AF.
Therefore, we studied whether the cancer patients’ AF contained
IgG that would bind to ovarian tumour cell antigens. The
membranes of Caov-3, PA-1, SK-OV-3 and SW626 cells were
isolated, electrophoresed in 5–15% SDS–PAGE slab gels, blotted
onto nitrocellulose filters and probed with dilutions of the AF
samples. Immunoglobulins in the AF samples from the ovarian
cancer patients reacted with several cell membrane antigens. IgG in
the AF sample no. 11 reacted with a 25kDa antigen in Caov-3, PA-
1 and SK-OV-3 cell membranes. The AF sample no. 13 reacted with
a 55kDa antigen in Caov-3, PA-1 and SK-OV-3 cell membranes.
The IgG in the AF sample no. 21 reacted with a 70kDa antigen in
Caov-3, PA-1 and SK-OV-3 cell membranes. In addition, AF IgG
from six patients (nos. 13, 14, 19, 20, 23 and 24) detected a 48kDa
antigen in PA-1 cells (Figure 6). In contrast, IgG in the AFs from
the control patients with liver failure did not detect any antigens
from the Caov-3, PA-1 or SK-OV-3 cell membranes.
DISCUSSION
In this study, we have observed tumour-reactive antibodies of the
IgG class, and a functionally active C system in the AF of most of
the examined patients with ovarian cancer. High levels of C
activation products in the AF samples and deposits of C1q and C3
on the isolated tumour cells indicate that the AF C system has
become activated in vivo. The tumour cells expressed membrane
bound C regulators on their surfaces and secreted their soluble
forms, as well as other soluble C inhibitors into their local
environment. These inhibitors are likely to restrict the cytotoxic
activity of AF against tumour cells. Our results suggest that
although the ovarian tumour cells in the malignant AF fluids are
surrounded by a functional C system, they are protected against C
activation. The tumour cells have C inhibitors on their cell
membranes and may also create a microenvironment where fluid
phase C activation is regulated. Therefore, if the ovarian tumour
cells are to be killed by tumour-specific mAbs and AF C, their
intrinsic C resistance, at least in part, must be overcome. This
could be achieved, in principle, with specific C regulator
neutralising antibodies.
The protein concentrations in malignant ovarian cancer AF
samples were 94–140% of those in serum, while the protein levels
in nonmalignant AFs were only 11–13.5% of serum values. These
data are similar to those reported earlier by others, and illustrate
the exudate and transudate natures of malignant and nonmalig-
nant AFs, respectively (Parsons et al, 1996). The substantially high
protein content in malignant AF is likely due to an increased
permeability of small blood vessels, release and shedding of
proteins from tumour cells, inflammatory and mesothelial cells
(Parsons et al, 1996), while the nonmalignant AF is a pure
transudate.
The antibodies of the IgG and IgM classes were present in
malignant AF at median concentrations of 8.12 and 0.33gl
 1,
respectively. IgM and IgG in AF might be derived both from
serum, and/or synthesised locally as a result of a local immune
response. The study by Guzman et al (1988) suggests that a portion
of ascitic Igs could be of local origin as AF contains both B cells
and plasma cells (Nakamura et al, 1978). As shown in Figure 5,
some of the AF IgG bound to distinct surface structures on the
ovarian cancer cells. The responses seemed to be individual as no
specific uniform binding pattern profile could be obtained for the
patient group as a whole. Antibodies present in the AF could act as
activators of the C system.
A functionally active C system was detected in the AF of patients
with ovarian cancer. In line with earlier studies (Runyon et al,
1985; Mal et al, 1991), the amounts of C3 and C4 were comparable
to those present in NHS. Both factors can be produced locally by
inflammatory and epithelial cells. To our knowledge this is the first
study examining the cytotoxic activity of C in malignant AF. Our
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Figure 3 Complement-mediated lysis of PA-1 and Caov-3 cells with
ascitic fluids from ovarian cancer patients. Caov-3 and PA-1 cells were
labelled with
51Cr. After sensitising with the anti-CD59 C-activating mAb
(YTH53.1; 350mgml
 1), the cells were exposed to ascites fluid (K)o r
normal human serum (J). The AF and serum dilutions are indicated on
the x-axis. The released radioactivity was counted from the supernatants
after a 30min incubation at 371C. Cell lysis was determined as a percentage
of the maximum releasable radioactivity: ((released radioactivity 
spontaneous release)/(maximum released radioactivity spontaneous
release)) 100%.
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AF. Classical and alternative pathway haemolytic activities were
seen in nine out of 12 and 12 out of 12 of the malignant AFs,
respectively. For most positive samples, the activity was at the level
of that present in NHS. In comparison, no such activity could be
found in the nonmalignant AF samples.
The presence of soluble C3a and SC5b-9 showed that the C
system in AF had become activated in vivo in many of the
patients. The concentrations of C3a and SC5b-9 were much
higher in patients with a neoplastic disease than in patients with
liver failure. Furthermore, on isolated tumour cells deposits of
C1q and C3d, but not of C5b-9, could be detected. This is an
original observation, and one of the first reports to show C
deposition on tumour cells in vivo. Complement activation may be
due to classical pathway activation initiated directly by membrane-
bound antibodies or indirectly by immune complexes in the
AF. Immune complex-induced C activation may lead to a
bystander attack against adjacent cells. Alternatively, activation
may have occurred by antibody-independent mechanisms,
either via the alternative pathway, or via a direct interaction of
C1q with exposed cell constituents like perturbed cellular
or mitochondrial membranes or chromatin. Tumour cells that
have become detached from their original sites may undergo
apoptotic (or necrotic) changes and expose binding sites for
C1q. This together with a reduced ability to control C could lead
to C activation.
To examine whether C in AF could kill viable tumour cells,
we tested the cytotoxic activity of the AF samples in a targeted
C-mediated killing assay. Different combinations of ovarian
tumour cell lines and AF samples were tested. By using a specific
C-activating mAb against the cell surface CD59-antigen (YTH53.1;
IgG2b), we found that it was possible to use the AF as a cytotoxic C
source. For most of the AF samples examined, the cytotoxic
activities were weaker than in the NHS samples tested for
comparison.
To investigate whether the tumour cells’ relative resistance to C
could be due to the expression of membrane regulators CD46,
CD55 and CD59, we performed immunohistochemical analysis of
tumour cells isolated from two patients with ovarian cancer. As
shown in Figure 4, MCP and CD59 were strongly expressed on all
the tumour cells. Decay-accelerating factor was more heteroge-
neously expressed as only 58 and 75% of the tumour cells showed
positive staining. The staining intensities varied both between the
samples and between the tumour cells from the individual patient.
The latter heterogeneity could, in part, be due to varying stages in
the tumour cells’ life cycles or to genomic instability that is a
general property of neoplastic cells (Fleuren et al, 1995). The
expression patterns found on the isolated and purified cancer cells
from the AF were similar to the expression patterns found earlier
in solid ovarian tumours (Bjrge L et al, 1997a).
We have previously shown that the amounts of alternative
pathway inhibitors FH/FHL-1 are higher in AF samples than in
sera (Junnikkala et al, 2002). The concentrations of FH/FHL-1 in
AF were relatively high (Table 2); nearly twice of those in sera. We
have observed that it is specifically the concentration of FHL-1
that is high in AF, and that functionally active FH and
FHL-1molecules are synthesised by the ovarian tumour cells
(Junnikkala et al, 2002). The small FHL-1molecule may thus act as
Figure 4 Immunohistochemical analysis of the expression of membrane bound C regulators on ovarian tumour cells isolated from AF. Cytotospin
specimens were fixed and stained with the mAbs BRIC 216 (A), J4-48 (B) and BRIC 229 (C) directed against DAF, MCP and CD59, respectively. An
irrelevant mouse IgG was used as a negative control (D). The bound mAbs were detected using an immunoperoxidase staining kit. Original magnification,
 200. Membrane cofactor protein and CD59 were strongly expressed by all the isolated tumour cells (B and C), while DAF expression was weaker and
more heterogeneous (A).
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Released soluble MCP may also have a similar, although a weaker
activity in the AF.
The amount of cell-free CD59 was found to be higher in AF than
in sera and in AF from patients with liver cirrhosis (Table 2). We
have shown earlier that ovarian and breast tumours of various
Figure 5 Immunohistochemical analysis of the C deposits on ovarian tumour cells isolated from AF. The cell specimens were stained with polyclonal
antibodies against C1q (A) and C3d (B) and a mAb directed against a TCC neoantigen (C). Normal rabbit serum was used as a negative control (D). The
bound Abs were detected using an immunoperoxidase staining kit, and the slides were counterstained with haematoxylin. Original magnifications,  40 (A)
and  200 (B, C and D). Deposits of C1q (A) and C3d (B), but not of C5b-9 (C), could be detected. No reactivity was seen when the primary antibody
was replaced with normal rabbit serum (D).
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Figure 6 Immunoblotting analysis of IgG in AF reacting with ovarian cancer cell membrane antigens. Cell membranes from Caov-3, PA-1, SK-OV-3 and
SW626 cells were isolated and electrophoresed in 5–15% SDS–PAGE gels and transferred onto nitrocellulose filters. The nitrocellulose strips were
incubated with the AF samples (diluted 1:800). Bound IgG was detected by the enhanced chemiluminescence system.
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shistological types all express high levels of CD59 (Hakulinen and
Meri, 1994; Bjrge L et al, 1997a;). The AF samples were obtained
from patients with a big tumour burden. The observation that AF
from patients with other large-sized gynaecological tumours of
different histological types (both malignant and benign) also
contained high levels of CD59 suggests that the release of CD59 from
cells is related to tumour mass rather than to the malignancy itself.
The full inhibitory activity of CD59 requires the presence of an
intact phospholipid tail that can incorporate into lipid bilayers.
Using a Triton X-114 phase separation method, an average of 80%
of AF CD59 was found to represent a form with anchor-associated
phospholipid. Similarly, phospholipid-tailed CD59 has been found
principally in amniotic fluid (Rooney and Morgan, 1992), seminal
plasma (Rooney et al, 1993) and in milk (Hakulinen and Meri,
1995). A proportion of CD59 may also be shed in small membrane
vesicles. The presence of a high level of phospholipid-containing
CD59 may in part explain the results of the functional analysis
showing that AF in general has a weaker C activity than NHS.
The presence of soluble forms of C membrane regulators in AF
is assumed to be due to release from tumour cells. The
immunoblotting experiments showed that the cultured ovarian
cancer cells can shed the C regulators CD46, CD55 and CD59 into
the culture medium. There is evidence that this is also the case
with tumours derived from other tissues (Bjrge L et al, 1994, 1996;
Jurianz et al, 1999; Hakulinen et al, 2004). It is likely that the C
regulators in AF, at least in part, are derived from the tumours
themselves. The secretion of both soluble C regulators, like FH/
FHL-1, and the release of membrane regulators can thus provide
additional resistance to ovarian tumours in the AF or at least
restrict the activity of the C system within the AF.
The presence of C activators and a functional C system in
malignant AF suggests that C attack against tumour cells
represents a partially operative immunological surveillance
mechanism. We have, however, shown that the AF C system has
an insufficient capacity to mediate effective C-mediated tumour
cell killing. The expression of membrane bound C regulators on
tumour cells and the release of C regulators may at least
partly explain the resistance. In addition, aggregated malignant
cells are more difficult to kill by C than single cells (Bjrge L et al,
1997b; Hakulinen and Meri, 1998), further contributing to the
tumour escape.
Recently, Ng et al (2002) have reported that the intraperitoneal
injection of the C activating mAb rituximab is an effective measure
to control recurrent abdominal ascites in non-Hodgkin’s lympho-
ma. In the case of ovarian cancer, the presence of tumour cells
within the peritoneal cavity surrounded by a functional C system
also makes this tumour type an attractive target for local
monoclonal antibody therapy (Markman, 1998). Although clinical
trials so far have failed to lead to any consistent response pattern,
it is possible that such therapy could be of considerable
benefit. Soluble as well as membrane regulators of C restrict
tumour cell lysis. However, the tumor cell killing by mAbs could
be improved if the activity of the C system within the peritoneal
space can be enhanced and the sensitivity of the tumour cells
increased, for example, by temporarily blocking C inhibitors. As
shown in the present study, the AF with its active C system
could provide effector mechanisms for mAb-mediated therapy of
ovarian tumours.
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